Shmuel Cabilly, Ph.D.

Dr. Cabilly holds a PhD in Immunology and is an investor and board member of several companies. He spent four years in the US as a postdoctoral fellow, heading a joint project of the City of Hope Research Institute and Genentech, where he developed a new technology for recombinant antibody production. This invention was patented in world patents, issued in the US 1989 and 2001. Today there are 20 drugs in the market based on this technology, including Herceptin, Rituxan, Traceba, Raptiva and Xolair. Dr. Cabilly was also a cofounder and a chief scientist of Ethrog Biotechnology (later sold to Invitrogen), where he invented two dry-buffer technologies.

Uri Halavee, Ph.D.

Dr. Halavee is a physicist and entrepreneur with a career in technology spanning more than 40 years. He is the head of Auriga Group, a privately held entrepreneurial partnership developing new technologies and investing in new initiatives. Dr. Halavee was the head of Soreq Research Center, Israel, and a cofounder and EVP of Opal Semiconductors, a NASDAQ company that later was acquired by Applied Materials for $200 million. He also cofounded X-Technologies, which developed a proprietary angioplasty catheter and was acquired by Guidant (NYSE:GDT) in 2003 for $160 million, and Kailight Photonics, a 40Gb optical communication company acquired by Optium in 2006 for $40 million. Dr. Halavee is the author of many scientific publications and holds many patents.

Shmuel Bukshpan, Ph.D.

Dr. Bukshpan is a physicist and entrepreneur with an extensive background in technology. He is the chief scientist of Auriga Group, a privately held entrepreneurial partnership developing new technologies and investing in new initiatives. He cofounded X-Technologies and Kailight Photonics. Dr. Bukshpan was the chief scientist at Soreq Research Center, Israel, is the author of many papers and holds numerous patents.

 

Ephraim Aharonson, Ph.D., MBA

Dr. Aharonson has a PhD in Physical Chemistry from the Weizmann Institute of Science, Israel, and earned an MBA from Recanati Business School at Tel Aviv University. He is an investor and development team member at Auriga. Prior to joining Auriga, Dr. Aharonson was a senior partner at Siemens Israel and head of the division for business development. Prior to that, he held various research and administrative positions at the Israeli Institute for Biological Research, including head of the Physical Chemistry Department, head of the Environmental Physics Department and deputy head of the Institute. Earlier, Dr. Aharonson served as a Research Associate in Respiratory Physiology at Johns Hopkins School of Hygiene & Public Health.